respiratori
viru
infect
import
caus
morbid
mortal
hematopoiet
cell
transplant
clinic
cours
sever
progress
lower
respiratori
tract
infect
coinfect
seriou
pulmonari
copathogen
high
mortal
nonmyeloabl
condit
regimen
achiev
engraft
without
erad
host
hematopoiet
cell
potenti
allow
protect
infect
commonli
seen
hematopoiet
cell
transplant
patient
treat
standard
intens
condit
regimen
perform
retrospect
cohort
studi
measur
incid
sever
parainfluenza
type
influenza
b
respiratori
synciti
viru
human
rhinoviru
diseas
myeloabl
versu
nonmyeloabl
versu
autolog
hematopoiet
cell
transplant
patient
incid
respiratori
viru
infect
similar
nonmyeloabl
myeloabl
cohort
less
autolog
cohort
respect
p
howev
respiratori
viru
lower
tract
infect
significantli
less
common
first
day
transplant
nonmyeloabl
patient
compar
myeloabl
autolog
patient
respect
respiratori
viru
lower
tract
infect
high
coinfect
attribut
mortal
rate
respiratori
viru
lower
tract
infect
first
day
hematopoiet
cell
transplant
less
common
person
receiv
nonmyeloabl
condit
regimen
compar
myeloabl
condit
despit
similar
overal
rate
acquisit
citat
schiffer
jt
kirbi
k
sandmaier
b
storb
r
corey
l
boeckh
time
sever
commun
acquir
respiratori
viru
infect
myeloabl
versu
nonmyeloabl
hematopoiet
stem
cell
transplant
abstract
jt
schiffer
et
al
haematologica
respiratori
viru
infect
hct
haematologica
f
e
r
r
r
f
u
n
n
jt
schiffer
et
al
haematologica
respiratori
viru
infect
hct
haematologica
f
e
r
r
r
f
u
n
n
jt
schiffer
et
al
haematologica
f
e
r
r
r
f
u
n
n
communityacquir
respiratori
infect
parainfluenza
influenza
b
respiratori
synciti
viru
rhinoviru
import
caus
morbid
mortal
hematopoiet
cell
transplant
though
incid
infect
hematopoiet
cell
transplant
patient
usual
parallel
commun
cours
sever
progress
lower
respiratori
tract
infect
coinfect
seriou
pulmonari
copathogen
invas
mold
late
airflow
declin
allogen
hematopoiet
cell
transplant
nonmyeloabl
reducedintens
condit
regimen
increasingli
common
modal
patient
age
comorbid
elig
convent
transplant
nonmyeloabl
condit
regimen
achiev
engraft
less
toxic
host
hematopoiet
cell
immedi
erad
potenti
allow
period
protect
infect
commonli
seen
hematopoiet
cell
transplant
patient
treat
standard
intens
condit
patient
place
nonmyeloabl
protocol
frequent
follow
outpati
patient
undergo
myeloabl
transplant
howev
graftversushost
diseas
therapi
continu
signific
risk
factor
invas
cytomegaloviru
fungal
infect
patient
undergo
nonmyeloabl
transplant
particularli
late
period
condit
unknown
whether
nonmyeloabl
condit
effect
acquisit
respiratori
viru
infect
likelihood
respiratori
viru
associ
lower
tract
infect
risk
progress
diseas
upper
lower
tract
infect
mortal
rate
associ
respiratori
viru
infect
perform
retrospect
cohort
studi
measur
incid
sever
infect
myeloabl
versu
nonmyeloabl
hematopoiet
cell
transplant
patient
decemb
march
patient
underw
myeloabl
hematopoiet
cell
transplant
fhcrc
allogen
autologoussyngen
tandem
ie
autolog
follow
plan
nonmyeloabl
hematopoiet
cell
transplant
six
month
later
cohort
includ
women
men
mean
age
year
rang
indic
transplant
includ
acut
leukemia
chronic
leukemia
lymphoma
myelodysplast
syndrom
myeloma
solid
tumor
aplast
anemia
caus
four
hundr
fortyeight
patient
underw
nonmyeloabl
hematopoiet
cell
transplant
includ
tandem
transplant
describ
tandem
patient
analyz
nonmyeloabl
cohort
cohort
includ
women
men
mean
age
year
rang
indic
transplant
includ
acut
leukemia
chronic
leukemia
lymphoma
myelodysplast
syndrom
myeloma
solid
tumor
caus
myeloabl
patient
condit
consist
cyclophosphamid
plu
either
total
bodi
irradi
busulfan
target
ngml
posttranspl
immunosuppress
usual
consist
cyclosporin
plu
methotrex
nonmyeloabl
patient
condit
total
bodi
irradi
alon
preced
fludarabin
mgm
dose
posttranspl
immunosuppress
consist
cyclosporin
tacrolimu
mycophenol
mofetil
autolog
hematopoiet
cell
transplant
recipi
typic
condit
cyclophosphamid
mgkg
etoposid
mgkg
fraction
total
bodi
irradi
hematopoiet
cell
transplant
patient
treat
inpati
start
condit
recoveri
neutropenia
thereaft
follow
twice
weekli
outpati
depart
day
transplant
return
care
refer
physician
autolog
hematopoiet
cell
transplant
patient
return
refer
physician
day
transplant
review
virolog
record
identifi
transplant
recipi
isol
parainfluenza
influenza
ab
respiratori
synciti
viru
human
rhino
viru
respiratori
secret
demonstr
viral
antigen
direct
fluoresc
antibodi
posit
convent
tube
cultur
posit
shell
vial
centrifug
cultur
respiratori
synciti
viru
infect
condit
exclud
extract
data
prospect
enter
databas
data
first
day
hematopoiet
cell
transplant
fhcrc
databas
longterm
followup
data
gather
fhcrc
databas
followup
medic
record
structur
correspond
letter
physician
outsid
fhcrc
nasopharyngealthroat
wash
swab
viral
direct
fluoresc
antibodi
stain
viral
cultur
standard
practic
patient
upper
respiratori
infect
symptom
throughout
studi
period
direct
fluoresc
antibodi
cultur
perform
bronchoalveolar
lavag
lung
biopsi
autopsi
specimen
cultur
hemadsorpt
direct
fluoresc
antibodi
techniqu
describ
elsewher
bronchoalveolar
biopsi
autopsi
specimen
submit
routin
bacteri
fungal
acidfast
bacilli
cultur
aspergillu
galactomannan
eia
direct
fluoresc
antibodi
stain
legionella
speci
cultur
cytospin
perform
cytomegaloviru
herp
simplex
viru
shell
vial
cultur
perform
cytomegaloviru
respiratori
synciti
viru
tube
cultur
inocul
four
cell
line
support
growth
herp
virus
respiratori
virus
parainfluenza
influenza
respiratori
synciti
viru
rhinoviru
upper
tract
infect
defin
isol
viru
nasopharyngealthroat
wash
cultur
evid
viral
specif
antigen
direct
fluoresc
antibodi
conjunct
consist
symptom
without
presenc
new
infiltr
chest
radiographi
parainfluenza
influenza
respiratori
synciti
viru
rhinoviru
lower
tract
infect
defin
isol
viru
cultur
evid
viral
specif
antigen
direct
fluoresc
antibodi
posit
respiratori
synciti
viru
shell
vial
centrifug
cultur
bronchoalveolar
lavag
lung
biopsi
specimen
associ
symptom
new
radiograph
infiltr
lower
tract
infect
includ
case
viru
first
detect
upper
respiratori
tract
detect
lavag
lung
biopsi
upper
tract
infect
consid
progress
lower
tract
viru
detect
lower
tract
h
upper
tract
presenc
copathogen
defin
isol
respiratori
viru
plu
pathogen
bacterium
mold
opportunist
viru
lavag
lung
biopsi
specimen
lavag
lung
biopsi
specimen
obtain
within
week
respiratori
viru
lower
tract
infect
diagnosi
attribut
mortal
defin
progress
respiratori
failur
presenc
respiratori
viru
lower
tract
infect
absenc
condit
thought
oncologist
pathologist
contribut
patient
death
posit
nasopharyngealthroat
wash
bronchoalveolar
lavag
respiratori
viru
patient
isol
prevent
transmiss
staff
patient
patient
underw
repeat
nasopharyngealthroat
wash
day
follow
identif
infect
weekli
document
clearanc
treatment
aerosol
ribavirin
respiratori
synciti
viru
parainfluenza
lower
tract
infect
perform
discret
treat
physician
dose
durat
g
mgml
administ
time
daili
two
hour
via
nebul
day
per
fhcrc
protocol
respiratori
synciti
viru
lower
tract
infect
patient
receiv
respiratori
synciti
viru
specif
monoclon
antibodi
discret
attend
physician
subset
parainfluenza
lower
tract
infect
patient
also
receiv
dose
intraven
immun
globulin
gkg
given
everi
day
other
immunosuppress
decreas
oseltamivir
becam
avail
influenza
use
thereaft
patient
treat
appropri
antibiot
antifung
agent
direct
copathogen
measur
incid
upper
lower
tract
infect
allogen
myeloabl
versu
allogen
nonmyeloabl
versu
autolog
hematopoiet
cell
transplant
patient
first
day
transplant
assum
patient
contribut
day
analysi
surviv
myeloabl
nonmyeloabl
transplant
exce
equal
group
pvalu
deriv
oneway
fisher
exact
test
determin
risk
factor
acquisit
parainfluenza
lower
tract
infect
progress
parainfluenza
upper
lower
tract
infect
logist
regress
model
fit
respiratori
viru
lower
tract
infect
outcom
day
zero
date
transplant
p
valu
regress
model
obtain
use
wald
test
adjust
made
multipl
comparison
incid
respiratori
viru
infect
slightli
lower
hematopoiet
cell
transplant
patient
follow
nonmyeloabl
condit
compar
myeloabl
condit
though
reach
statist
signific
incid
respiratori
viru
infect
higher
allogen
hematopoiet
cell
transplant
patient
autolog
patient
tabl
cumul
incid
autolog
cohort
track
allogen
myeloabl
cohort
day
figur
expect
trend
data
autolog
transplant
patient
less
reliabl
beyond
day
transplant
patient
typic
return
outsid
provid
parainfluenza
common
infect
follow
respiratori
synciti
viru
influenza
rhinoviru
tabl
influenza
infect
occur
predomin
winter
rsv
infect
typic
occur
late
winter
parainfluenza
infect
occur
year
round
detect
differ
season
pattern
nonmyeloabl
myeloabl
cohort
data
shown
respiratori
tract
diseas
case
lower
tract
infect
one
case
lower
tract
infect
patient
underw
nonmyeloabl
condit
caus
agent
case
rhinoviru
whose
role
uncommon
potenti
lethal
lung
pathogen
hematopoiet
cell
transplant
patient
becom
clear
incid
respiratori
viru
lower
tract
infect
lower
patient
underw
nonmyeloabl
condit
compar
patient
underw
myeloabl
condit
follow
either
allogen
autolog
transplant
tabl
percentag
viral
respiratori
tract
infect
result
lower
tract
infect
significantli
lower
patient
nonmyeloabl
cohort
compar
allogen
myeloabl
cohort
percentag
case
viral
respiratori
tract
infect
result
lower
tract
infect
significantli
higher
autolog
cohort
compar
allogen
myeloabl
cohort
probabl
due
artifici
low
cumul
incid
total
respiratori
infect
autolog
patient
tabl
differ
lower
tract
infect
nonmyeloabl
myeloabl
cohort
due
differ
incid
parainfluenza
infect
clinic
characterist
avail
patient
parainfluenza
lower
tract
infect
patient
upper
tract
infect
tabl
univari
logist
regress
analysi
parainfluenza
low
absolut
lymphocyt
count
cellsmm
first
day
infect
p
correl
higher
likelihood
lower
tract
infect
nonmyeloabl
condit
associ
nonsignific
lower
likelihood
lower
tract
infect
multivari
analysi
absolut
lymphocyt
count
less
cellsmm
correl
increas
risk
lower
tract
infect
tabl
respiratori
viru
lower
tract
infect
notabl
high
rate
coinfect
mechan
ventil
attribut
mortal
fortyon
percent
parainfluenza
influenza
respiratori
synciti
viru
infect
notabl
isol
anoth
virul
pathogen
pathogen
includ
aspergillu
speci
cytomegaloviru
pseudomona
speci
legionella
speci
stenotrophomona
mirabella
catarrhali
klebsiella
pneumonia
cytomegaloviru
isol
influenza
lower
tract
infect
compar
parainfluenza
lower
tract
infect
aspergillu
speci
isol
influenza
lower
tract
infect
compar
parainfluenza
infect
rate
mechan
ventil
lower
respiratori
infectionattribut
mortal
parainfluenza
influenza
respiratori
synciti
viru
infect
fewer
patient
develop
viral
upper
respiratori
tract
infect
nonmyeloabl
condit
die
within
day
infect
patient
develop
upper
respiratori
tract
infect
myeloabl
condit
figur
respiratori
synciti
viru
lower
tract
infect
parainfluenza
infect
treat
inhal
ribavirin
seventeen
parainfluenza
patient
receiv
intraven
immunoglobulin
therapi
three
five
influenza
case
receiv
oseltamivir
receiv
amantadin
rimantadin
therapi
three
respiratori
synciti
viru
infect
patient
receiv
intraven
immunoglobulin
respiratori
synciti
virusdirect
immunoglobulin
eleven
percent
serotyp
parainfluenza
case
respect
seventyf
percent
type
influenza
case
influenza
influenza
b
respect
enough
data
compar
clinic
outcom
viral
subtyp
total
durat
followup
patient
respiratori
viru
diseas
cumul
incid
total
respiratori
viru
infect
day
hematopoiet
cell
transplant
significantli
differ
patient
follow
nonmyeloabl
myeloabl
plu
autolog
transplant
cumul
incid
total
lower
tract
infect
occur
day
transplant
also
result
indic
first
day
hematopoiet
cell
transplant
allogen
nonmyeloabl
myeloabl
transplant
patient
similar
rate
respiratori
viru
infect
patient
undergo
autolog
hematopoiet
cell
transplant
smaller
incid
respiratori
viru
infect
howev
cumul
incid
respiratori
viru
infect
first
day
allogen
myeloabl
autolog
cohort
nearli
ident
reason
lower
cumul
incid
infect
autolog
transplant
day
like
truncat
followup
system
transplant
rather
biolog
effect
typic
season
three
virus
demonstr
though
pattern
season
infect
differ
myeloabl
nonmyeloabl
cohort
despit
compar
number
infect
incid
lower
tract
infect
first
day
hematopoiet
cell
transplant
lower
patient
underw
nonmyeloabl
condit
nonsignific
decreas
incid
parainfluenza
lower
tract
infect
one
patient
receiv
nonmyeloabl
condit
develop
lower
tract
infect
first
day
transplant
absenc
parainfluenza
influenza
respiratori
synciti
viru
lower
tract
infect
nonmyeloabl
transplant
patient
consist
hypothesi
persist
host
cell
might
result
protect
seriou
infect
though
evid
need
definit
prove
point
data
reveal
equal
incid
respiratori
viru
infect
lower
tract
infect
among
nonmyeloabl
myeloabl
cohort
beyond
day
transplant
signifi
limit
durat
protect
immun
nonmyeloabl
cohort
transit
preponder
earlyonset
lateonset
infect
describ
invas
fungi
cytomegaloviru
parainfluenza
infect
account
statist
differ
two
cohort
common
viru
isol
high
dose
corticosteroid
graft
versu
host
diseas
lymphopenia
risk
factor
progress
parainfluenza
upper
lower
tract
infect
perhap
due
decreas
tcell
immun
current
analysi
corticosteroid
dose
correl
progress
lower
tract
infect
possibl
base
polici
attempt
reduc
steroid
dose
patient
infect
parainfluenza
introduc
follow
analysi
earlier
cohort
anoth
risk
factor
lower
tract
infect
parainfluenza
infect
rather
type
though
clinic
data
need
confirm
find
novel
observ
might
suggest
factor
relat
pathogen
host
predict
sever
diseas
respiratori
viru
pneumonia
carri
high
mortal
rate
associ
invas
mold
pathogen
bacteria
virus
seen
immunocompromis
host
particularli
high
rate
cytomegaloviru
infect
case
influenza
notabl
gener
poor
outcom
group
patient
develop
respiratori
synciti
viru
infect
less
like
die
infect
patient
parainfluenza
influenza
possibl
due
earli
therapi
inhal
ribavirin
palivizumab
though
interpret
caution
base
small
number
lower
tract
infect
patient
cohort
strength
analysi
includ
larg
sampl
size
standard
diagnost
approach
hematopoiet
cell
transplant
patient
respiratori
symptom
limit
includ
retrospect
natur
use
convent
diagnost
test
lack
sensit
polymeras
chain
reaction
well
lack
quantit
assay
measur
diseas
sever
exclus
respiratori
virus
detect
pcr
human
metapneumoviru
coronaviru
anoth
weak
routin
molecular
test
virus
virus
includ
studi
includ
quantit
measur
routin
perform
center
elsewher
time
period
retrospect
cohort
data
collect
day
allogen
hematopoiet
cell
transplant
day
autolog
transplant
interpret
caution
reliant
upon
accur
report
outsid
physician
probabl
low
morbid
event
underrepres
conclus
respiratori
viru
lower
tract
infect
first
day
hematopoiet
cell
transplant
significantli
less
common
person
receiv
nonmyeloabl
condit
despit
similar
overal
rate
acquisit
respiratori
viru
lower
tract
infect
high
coinfect
mortal
rate
screen
respiratori
virus
continu
hematopoiet
cell
transplant
patient
although
patient
nonmyeloabl
protocol
likelihood
develop
respiratori
viru
lower
tract
infect
low
first
day
hematopoiet
cell
transplant
low
risk
progress
lower
tract
infect
among
nonmyeloabl
transplant
recipi
suggest
intrigu
possibl
use
condit
regimen
patient
develop
respiratori
viru
diseas
transplant
case
delay
transplant
resolut
infect
current
recommend
especi
infect
due
respiratori
synciti
viru
parainfluenza
influenza
howev
delay
may
increas
risk
progress
underli
hematolog
malign
thu
nonmyeloabl
condit
may
provid
safer
altern
transplant
urgent
evalu
approach
need
jt
mb
particip
concept
design
analysi
interpret
data
draft
critic
revis
articl
import
intellectu
content
final
approv
version
publish
kk
particip
analysi
interpret
data
draft
articl
final
approv
version
publish
bs
rs
particip
analysi
interpret
data
revis
articl
critic
import
intellectu
content
final
approv
version
publish
lc
particip
concept
design
studi
revis
critic
import
intellectu
content
final
approv
version
publish
sourc
support
nih
ca
ca
ca
ca
hl
hl
author
report
potenti
conflict
interest
